Pacira BioSciences, Inc.PCRX

Pacira BioSciences Inc. last filed its quarterly accounts on 31 March 2026 and the numbers read like a company that has decided tranquillity is a core competence. Revenue clocked in at $177.4 million, net income was $2.9 million, and the balance sheet kept $144.3 million in cash plus $57.9 million in short-term investments, all without a single squeak about dilution or desperate capital calls. Operating income of $6.9 million sat comfortably between the two, while inventory sat at $150.4 million and even shrank by $2.5 million during the period - hardly the behaviour of a business in a hurry. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1396814/000162828026013845/000162828026013845.htm)

The company’s pipeline is polite rather than explosive. PCRX-201, an investigational gene therapy for chronic inflammation in knee osteoarthritis, promises to boost cellular IL-1Ra production and block IL-1 pathway activation when injected locally - a neat trick if it pans out. Its companion, PCRX-2002, is a hydrogel designed to deliver rapid and extended release of ropivacaine from a single application at surgery, currently marching toward a phase 2 bunionectomy study. Both are filed under the same “innovation” heading as EXPAREL, iovera°, and ZILRETTA, all of which carry Pacira’s trademark shield. The science pages are glossy; the accounts are quiet. (source: Pacira product rails, https://www.pacira.com/innovation/clinical-trials/, https://www.pacira.com/innovation/pcrx-201/, https://www.pacira.com/innovation/pcrx-2002/, https://www.pacira.com/innovation/pipeline/)

In the quarter, Pacira burned $28.1 million on research and development but tucked $2.7 million into property, plant and equipment, leaving free cash flow at $23.0 million. Diluted EPS came in at $0.07 on 40.9 million shares, while liabilities of $554.6 million sat against equity of $653.9 million. The cash position is strong enough to cover obligations without tapping the shelf, and the company’s pMVL technology - the proprietary multivesicular liposome platform - remains the quiet engine behind its drug-delivery franchise. No dividends, no buybacks, no debt bombs, and no sudden inventory surges. Just four products, one platform, and a balance sheet that seems content to be average. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1396814/000162828026013845/000162828026013845.htm)

For investors who like to see the source behind the story, the company’s SEC filings index and company facts JSON are kept up to date on EDGAR, while the clinical pipelines and product pages live on Pacira’s own site. The SEC rails confirm the numbers; the product rails confirm the ambitions. What is not confirmed is any inflection point - no new approvals, no accelerated timelines, no surprise catalyst beyond a phase 2 bunionectomy study that could read through to a broader pain portfolio. Until then, the market file is less a thriller and more a steady-state observation. (source: SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=1396814; Pacira product rails, https://www.pacira.com/innovation/pcrx-2002/)

If you want a chart, the company is listed on Nasdaq under the ticker PCRX and you can pull the daily candles from any standard terminal. The file here focuses on the operating facts that the filings actually supply, not the price action they do not. A 10-Q, six Form 4s, and a handful of product pages are the full extent of the evidence set today. Anything beyond that - analyst notes, valuation commentary, trading volumes, or liquidity depth - is not in the source pack and therefore not in this report. (source: SEC EDGAR submissions JSON, https://data.sec.gov/submissions/CIK0001396814.json; TradingView route implied, not specified in evidence)